Views
1287 of 1287 companies
| Company | Pipeline | Most advanced | Next readout |
|---|---|---|---|
 Oruka TherapeuticsORKA · Nasdaq | 2 assets: 2 Ph 2 | ORKA-001Phase 2 · Psoriasis | Jan 2027ORKA-002 · Phase 1 |
 Palobiofarma SLPrivate | 2 assets: 1 Ph 2, 1 Ph 1 | PBF-680Phase 2 · AsthmaPartial signal | None on record |
 PharmaMarPHM · BME | 2 assets: 1 approved, 1 Ph 3 | PlitidepsinPhase 3 · Multiple MyelomaPartial signal | 28 Jan 2028Lurbinectedin · Phase 1/2 |
Poseida Therapeutics, Inc.Private | 2 assets: 2 Ph 1 | P-BCMA-ALLO1Phase 1 · Multiple Myeloma | Mar 2029P-BCMA-ALLO1 · Phase 1 |
 Prelude TherapeuticsPRLD · Nasdaq | 2 assets: 1 Ph 2, 1 Ph 1 | PRT3789Phase 2 · Non-Small Cell Lung CancerWeak signal | None on record |
 Prevail TherapeuticsPrivate | 2 assets: 1 Ph 2, 1 Ph 1 | PR001 (LY3884961)Phase 1/2 · Parkinson's Disease | Feb 2027PR001 (LY3884961) · Phase 1/2 |
| 2 assets: 1 Ph 2, 1 other | QR-333Phase 2 · Diabetic Peripheral Neuropathy | None on record | |
 Processa Pharmaceuticals, Inc.PCSA · Nasdaq | 2 assets: 1 Ph 2, 1 other | PCS6422Phase 2 · Metastatic Colorectal Cancer | None on record |
 Protagonist TherapeuticsPTGX · Nasdaq | 2 assets: 1 approved, 1 Ph 3 | rusfertidePhase 3 · Polycythemia Vera | 10 Feb 2027icotrokinra · Phase 3 |
 Protalix BioTherapeutics, Inc.PLX · NYSE American | 2 assets: 1 approved, 1 Ph 2 | PRX-115Phase 2 · Severe Refractory Gout | Dec 2027PRX-115 · Phase 2 |
 Provectus PharmaceuticalsPVCT · OTC | 2 assets: 1 Ph 2, 1 other | PH-10Phase 2 · PsoriasisPartial signal | None on record |
 Puma BiotechnologyPBYI · Nasdaq | 2 assets: 1 approved, 1 Ph 3 | AlisertibPhase 3 · Small Cell Lung Cancer | 30 Oct 2027Alisertib · Phase 2 |
 PureTech HealthPTCHF · OTC | 2 assets: 2 Ph 2 | GlyphAllo (allopregnanolone prodrug)Phase 2 · Major Depressive Disorder | Mar 2027GlyphAllo (allopregnanolone prodrug) · Phase 2 |
 RANI TherapeuticsRANI · Nasdaq | 2 assets: 1 Ph 2, 1 Ph 1 | PG-102Phase 2 · ObesityPartial signal | 1 Dec 2026PG-102 · Phase 1 |
 Recursion PharmaceuticalsRXRX · Nasdaq | 2 assets: 1 Ph 3, 1 Ph 2 | REC-2282Phase 2/3 · Meningioma | None on record |
 Regor PharmaceuticalsPrivate | 2 assets: 2 Ph 2 | regor GLP-1Phase 2 · ObesityPartial signal | 30 Dec 2026RGT-419B · Phase 1 |
 Reistone BiopharmaPrivate | 2 assets: 1 Ph 3, 1 Ph 2 | RSS0393Phase 3 · PsoriasisPartial signal | Jan 2027RSS0393 · Phase 3 |
 Relay Therapeutics, Inc.RLAY · Nasdaq | 2 assets: 1 Ph 3, 1 Ph 2 | ZovegalisibPhase 3 · HR+/HER2- Metastatic Breast Cancer | 30 Apr 2027Zovegalisib · Phase 1 |
| 2 assets: 1 Ph 3, 1 Ph 2 | JS105Phase 3 · HR+/HER2- Metastatic Breast Cancer | 26 Feb 2027JS105 · Phase 1/2 | |
 S.Biomedics304360 · KOSDAQ | 2 assets: 2 Ph 2 | Adipose-derived MSC clusters (S.Biomedics)Phase 1/2 · Atherosclerotic Cardiovascular DiseaseWeak signal | 7 Feb 2029TED-A9 (A9-DPC) · |
 SK Biopharmaceuticals Co., Ltd.326030 · KOSPI | 2 assets: 1 approved, 1 Ph 3 | CarisbamatePhase 3 · EpilepsyPartial signal | Nov 2026Cenobamate · Phase 3 |
 SNLD, Ltd.Private | 2 assets: 1 Ph 2, 1 Ph 1 | TR-012001Phase 2 · Parkinson's DiseasePartial signal | None on record |
 Samsung Biologics207940 · KOSPI | 2 assets: 2 approved | Approved assets only | None on record |
 Sangamo TherapeuticsSGMOQ · OTC | 2 assets: 2 other | isaralgagene civaparvovecFabry Disease | None on record |
 Sanwa Kagaku KenkyushoPrivate | 2 assets: 1 approved, 1 Ph 3 | UpacicalcetPhase 3 · Chronic Kidney DiseasePartial signal | None on record |
| 2 assets: 1 Ph 3, 1 Ph 2 | Galinpepimut-SPhase 3 · Acute Myeloid LeukemiaWeak signal | 30 Dec 2026SLS009 · Phase 1/2 | |
 Senti BiosciencesSNTI · | 2 assets: 1 Ph 1, 1 other | SENTI-202Phase 1 · Acute Myeloid Leukemia | None on record |
 Seres TherapeuticsMCRB · Nasdaq | 2 assets: 1 approved, 1 other | SER-155Bacterial Infections in Allogeneic Stem Cell Transplant | None on record |
| 2 assets: 2 Ph 1 | BZE2204Phase 1 · Systemic Lupus Erythematosus | 31 Dec 2026CD19/CD20/BCMA CAR-T (Shanghai Cell Therapy Group) · Phase 1 | |
| 2 assets: 1 Ph 3, 1 Ph 2 | HB0034Phase 2/3 · Psoriasis | None on record | |
| 2 assets: 1 Ph 3, 1 Ph 2 | LW402Phase 3 · Atopic DermatitisPartial signal | Mar 2027LW231 · Phase 1/2 | |
Shanghai Pharmaceuticals Holding2607 · SSE | 2 assets: 2 Ph 3 | sitokirenPhase 3 · HypertensionPartial signal | 1 Dec 2026SPH4336 · Phase 2/3 |
| 2 assets: 1 Ph 2, 1 Ph 1 | ARX-F01 (sufentanil sublingual tablet)Phase 2 · Systemic Lupus Erythematosus | None on record | |
| 2 assets: 1 Ph 3, 1 Ph 2 | VGN-R09bPhase 2/3 · Parkinson's Disease | 1 Sep 2027VGN-R08b · Phase 1/2 | |
| 2 assets: 2 Ph 3 | SupaglutidePhase 2/3 · Type 2 DiabetesReliable signal | 30 Apr 2027efsubaglutide alfa · Phase 1 | |
| 2 assets: 2 Ph 2 | LipovirtidePhase 2 · HIVPartial signal | None on record | |
| 2 assets: 2 Ph 2 | INV-6452Phase 1/2 · HR+/HER2- Metastatic Breast Cancer | 4 Feb 2028INV-6452 · Phase 1/2 | |
 Shionogi4507 · TSE | 2 assets: 2 Ph 3 | PravafenixPhase 3 · Atherosclerotic Cardiovascular DiseasePartial signal | None on record |
 Sirius TherapeuticsPrivate | 2 assets: 2 Ph 2 | SRSD107Phase 2 · Atherosclerotic Cardiovascular Disease | Dec 2027SRSD107 · Phase 2 |
 Stemline Therapeutics, Inc.Private | 2 assets: 1 approved, 1 Ph 2 | TagraxofuspPhase 2 · Acute Myeloid LeukemiaWeak signal | Nov 2026Elacestrant · Phase 2 |
 Sunho Biologics2898 · HKEX | 2 assets: 1 Ph 2, 1 Ph 1 | IAP0971Phase 1/2 · Non-Small Cell Lung Cancer | 28 Feb 2027ISH0688 · Phase 1 |
 Suven Life SciencesSUVEN · NSE | 2 assets: 1 Ph 3, 1 Ph 2 | MasupirdinePhase 3 · Alzheimer's DiseasePartial signal | Dec 2026Masupirdine · Phase 3 |
 Suzhou AlphamabPrivate | 2 assets: 1 Ph 3, 1 Ph 2 | EnvafolimabPhase 3 · Non-Small Cell Lung CancerWeak signal | 30 Dec 2026KN060 · Phase 1 |
| 2 assets: 1 Ph 3, 1 Ph 2 | YK-209APhase 3 · Non-Small Cell Lung Cancer | None on record | |
 Suzhou Ribo Life Science6938 · HKEX | 2 assets: 1 Ph 2, 1 Ph 1 | RBD5044Phase 2 · Atherosclerotic Cardiovascular Disease | None on record |
 Suzhou Sanegene BioPrivate | 2 assets: 1 Ph 2, 1 Ph 1 | IBI3016Phase 2 · Hypertension | 30 Jan 2027IBI3016 · Phase 1 |
 Suzhou Siran BiotechnologyPrivate | 2 assets: 2 Ph 1 | SA030Phase 1 · Obesity | 30 Mar 2027SA1211 injection · Phase 1 |
 Suzhou Yabao PharmaceuticalPrivate | 2 assets: 2 Ph 2 | SY-004Phase 2 · Type 2 DiabetesPartial signal | None on record |
 Suzhou Zelgen Biopharmaceuticals688266 · SSE STAR Market | 2 assets: 1 Ph 3, 1 Ph 2 | jaktinibPhase 3 · Atopic DermatitisPartial signal | Apr 2027ZG005 · Phase 1/2 |
 Swedish Orphan Biovitrum AB (publ)SOBI · Nasdaq Stockholm | 2 assets: 1 approved, 1 Ph 3 | PegcetacoplanPhase 3 · Chronic Kidney Disease | 25 Jun 2027Pegcetacoplan · Phase 2 |
 SyndaxSNDX · | 2 assets: 2 approved | Approved assets only | Feb 2027Revumenib · Phase 1 |
 Syndeio BiosciencesPrivate | 2 assets: 2 Ph 2 | ApimostinelPhase 2 · Major Depressive DisorderPartial signal | Sep 2027Zelquistinel · Phase 2 |
 SystImmunePrivate | 2 assets: 1 Ph 3, 1 Ph 1 | BL-M11D1Phase 2/3 · Acute Myeloid Leukemia | None on record |
 TJ Biopharma Co., Ltd.Private | 2 assets: 2 Ph 3 | TJ202Phase 3 · Multiple MyelomaPartial signal | 5 Aug 2028Uliledlimab · Phase 2/3 |
 TScan Therapeutics, Inc.TCRX · Nasdaq | 2 assets: 1 Ph 3, 1 Ph 1 | TSC-101Phase 3 · Hematologic Malignancies | Jun 2029TSC-101 · Phase 3 |
 TaiMed Biologics4147 · TPEx | 2 assets: 1 approved, 1 Ph 2 | TMB-365 / TMB-380Phase 2 · HIV | May 2027TMB-365 / TMB-380 · Phase 2 |
 TheratechnologiesPrivate | 2 assets: 2 approved | Approved assets only | None on record |
 Theravance BiopharmaPrivate | 2 assets: 1 approved, 1 Ph 3 | Ampreloxetine (TD-9855)Phase 3 · Neurogenic Orthostatic HypotensionPartial signal | None on record |
 Tianjin Hemay PharmaceuticalPrivate | 2 assets: 1 Ph 3, 1 Ph 2 | Hemay005Phase 3 · Ulcerative ColitisPartial signal | None on record |
Tonghua Dongbao Pharmaceutical600867 · SSE | 2 assets: 1 Ph 3, 1 Ph 2 | THDB0206Phase 3 · Type 2 DiabetesPartial signal | None on record |
 Tubulis GmbHPrivate | 2 assets: 2 Ph 2 | TUB-040Phase 2 · Non-Small Cell Lung Cancer | Dec 2027TUB-040 · Phase 1/2 |
US WorldMeds, LLCPrivate | 2 assets: 1 approved, 1 Ph 2 | letetresgene autoleucelPhase 2 · Myxoid/Round Cell Liposarcoma | None on record |
| 2 assets: 1 Ph 3, 1 Ph 1 | UBT251Phase 3 · Obesity | 25 Oct 2026UBT38006 · Phase 1 | |
 Upsher-Smith Laboratories, LLC6472 · TWSE | 2 assets: 2 approved | Approved assets only | None on record |
 VIVUSPrivate | 2 assets: 1 approved, 1 Ph 3 | Extended-release tacrolimus (VI-0106)Phase 3 | 31 May 2028Extended-release tacrolimus (VI-0106) · Phase 3 |
 VaxxinityVAXX · OTC | 2 assets: 1 Ph 1, 1 other | UB-312Phase 1 · Parkinson's DiseasePartial signal | None on record |
| 2 assets: 2 Ph 2 | VENT-03Phase 2 · Systemic Lupus Erythematosus | None on record | |
 Veru Inc.VERU · Nasdaq | 2 assets: 1 Ph 3, 1 Ph 2 | enobosarmPhase 3 · ObesityPartial signal | Oct 2027enobosarm · Phase 2 |
 Verve TherapeuticsPrivate | 2 assets: 1 Ph 2, 1 Ph 1 | VERVE-102Phase 2 · Atherosclerotic Cardiovascular Disease | Dec 2027VERVE-201 · Phase 1 |
 Vigonvita Life Sciences2630 · HKEX | 2 assets: 2 Ph 2 | LV232Phase 2 · Major Depressive DisorderWeak signal | 31 Oct 2027VV119 · Phase 2 |
 Voyager TherapeuticsVYGR · Nasdaq | 2 assets: 1 Ph 2, 1 other | VY7523Phase 1/2 · Alzheimer's Disease | May 2027VY7523 · Phase 1/2 |
| 2 assets: 1 Ph 1, 1 other | WTX-124Phase 1 · Advanced or Metastatic Solid Tumors | None on record | |
 Windtree TherapeuticsWINT · OTC | 2 assets: 1 Ph 3, 1 other | IstaroximePhase 2/3 · Heart FailurePartial signal | None on record |
 Wuhan YZY Biopharma Co., Ltd.2496 · HKEX | 2 assets: 1 Ph 3, 1 Ph 1 | M701Phase 3 · Non-Small Cell Lung Cancer | None on record |
 XBiotechXBIT · Nasdaq | 2 assets: 1 Ph 2, 1 other | NatrunixPhase 2 · Rheumatoid ArthritisPartial signal | 15 Jan 2027Natrunix · Phase 2 |
 YS Biopharma Co., Ltd.Private | 2 assets: 2 other | PIKA Rabies VaccineRabies Prevention and Post-Exposure Prophylaxis | None on record |
 Zambon SpAPrivate | 2 assets: 1 approved, 1 Ph 1 | ZP-059Phase 1 · AsthmaWeak signal | None on record |
| 2 assets: 1 Ph 2, 1 Ph 1 | JX11502MAPhase 1/2 · SchizophreniaPartial signal | None on record | |
Zhimeng BiopharmaPrivate | 2 assets: 1 Ph 3, 1 Ph 1 | CB03-154Phase 2/3 · Epilepsy | Sep 2027CB03-154 · Phase 2 |
 iCamuno Biotherapeutics Ltd.Private | 2 assets: 2 Ph 1 | ALC01Phase 1 · Parkinson's Disease | 15 Dec 2027ALC01 · Phase 1 |
 iOncturaPrivate | 2 assets: 2 Ph 2 | IOA-244Phase 1/2 · Non-Small Cell Lung Cancer | Jan 2027IOA-244 · Phase 1/2 |
| 1 asset: 1 Ph 1 | bb21217Phase 1 · Multiple MyelomaWeak signal | None on record | |
 35PharmaPrivate | 1 asset: 1 Ph 2 | HS235Phase 1/2 · Hypertension | Mar 2028HS235 · Phase 1/2 |
 3D Medicines Inc.1244 · HKEX | 1 asset: 1 Ph 1 | 3D189Phase 1 · Multiple Myeloma | None on record |
4D pharma plcPrivate | 1 asset: 1 Ph 1 | MRx-4DP0004Phase 1 · AsthmaPartial signal | None on record |
 7 Hills Pharma, LLCPrivate | 1 asset: 1 Ph 2 | AlintegimodPhase 1/2 · Non-Small Cell Lung Cancer | 31 Dec 2027Alintegimod · Phase 1/2 |
 89bioPrivate | 1 asset: 1 Ph 3 | PegozaferminPhase 3 · Atherosclerotic Cardiovascular DiseasePartial signal | Jun 2028Pegozafermin · Phase 3 |
A&G Pharmaceutical Inc.Private | 1 asset: 1 Ph 1 | AG-01Phase 1 · Non-Small Cell Lung Cancer | None on record |
 A. MenariniPrivate | 1 asset: 1 Ph 3 | RanolazinePhase 3 · Atherosclerotic Cardiovascular DiseasePartial signal | None on record |
 ABLi Therapeutics, Inc.Private | 1 asset: 1 Ph 2 | Risvodetinib (IkT-148009)Phase 2 · Parkinson's DiseasePartial signal | None on record |
 ABM Therapeutics CorporationPrivate | 1 asset: 1 Ph 1 | ABM-1310Phase 1 · Non-Small Cell Lung Cancer | None on record |
 ABVC BioPharmaABVC · Nasdaq | 1 asset: 1 Ph 2 | PDC-1421Phase 2 · Major Depressive DisorderPartial signal | 28 Feb 2028PDC-1421 · Phase 1/2 |
 ACEA TherapeuticsPrivate | 1 asset: 1 Ph 2 | STI-6129Phase 1/2 · Multiple Myeloma | 31 Dec 2026STI-6129 · Phase 1/2 |
| 1 asset: 1 Ph 1 | ADEL-Y01Phase 1 · Alzheimer's DiseasePartial signal | None on record | |
 ADvantage TherapeuticsPrivate | 1 asset: 1 Ph 2 | AD04Phase 2 · Alzheimer's Disease | Dec 2026AD04 · Phase 2 |
 AGIOS PHARMACEUTICALS, INC.AGIO · Nasdaq | 1 asset: 1 approved | Approved assets only | Mar 2029Mitapivat · Phase 3 |
 AOBiomePrivate | 1 asset: 1 Ph 2 | Nitrosomonas eutropha (B244)Phase 2 · Atopic DermatitisReliable signal | None on record |
 AP Biosciences Inc.6945 · TPEx | 1 asset: 1 Ph 2 | AP203Phase 1/2 · Non-Small Cell Lung Cancer | Dec 2026AP203 · Phase 1/2 |
 APRINOIA TherapeuticsPrivate | 1 asset: 1 Ph 1 | APNmAb005Phase 1 · Alzheimer's DiseasePartial signal | None on record |
| 1 asset: 1 Ph 2 | BucindololPhase 2 · Heart FailurePartial signal | None on record |
Next readout: the earliest estimated primary completion of a trial the company or a partner on the asset runs (ClinicalTrials.gov).